Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits

Merck & Co’s Marshall To Take Over

 
• By Andrew McConaghie

A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.

Novartis NIBR Cambridge, MA
Bradner has headed up the Cambridge, MA-headquartered NIBR since 2016, but will hand over to Fiona Marshall in November. • Source: Shutterstock

More from Immunological

More from Therapy Areas